This study is looking at two different treatments, Intercept Fibrinogen Complex (IFC) and Cryoprecipitate Antihemophilic Factor (AHF), for patients undergoing liver transplant surgery who have bleeding and low fibrinogen (a protein important for blood clotting). The goal is to see if IFC, which can be given more quickly, works as well as AHF in reducing the amount of blood products needed. You might be able to join if you are 18 or older, scheduled for a cadaveric liver transplant, and have certain conditions like low fibrinogen or alcoholic cirrhosis. The study is currently recruiting participants.

Study design

This is a pilot study that will randomly assign participants to receive either Intercept Fibrinogen Complex (IFC) or Cryoprecipitate Antihemophilic Factor (AHF). It will include about 60 participants and is not blinded, meaning both you and your doctors will know which treatment you are receiving.

What's involved

The main measurement for this study is the amount of blood products you receive within 24 hours after the initial blood product administration.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of the study is measured 24 hours after the initial blood product administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.